Entecavir as a Preferred Hepatitis B Treatment Option in Severe Renal Impairment

In patients with severe renal impairment defined as a creatinine clearance of less than 15 mL/min or in those with a history of intolerance to tenofovir-based agents such as tenofovir disoproxil fumarate or tenofovir alafenamide, entecavir stands out as an appropriate and well-supported alternative for hepatitis B management, David Ha, PharmD, lecturer of medicine at Stanford University School of Medicine, said. Tenofovir-containing products are generally not recommended in this population due to renal safety concerns, making entecavir a practical consideration in this clinical scenario.

According to the 2026 American Association for the Study of Liver Disease and Infectious Diseases Society of America guidelines for hepatitis B treatment, entecavir remains a cornerstone of therapy across a broad range of patients. It offers several notable advantages including being generally low-cost, widely covered by insurance, highly efficacious, and well tolerated. Although concerns about antiviral resistance exist, the absolute risk remains quite low—approximately 1% over a 6-year period—making it a reliable long-term option. For pharmacists managing hepatitis B in patients where tenofovir-based regimens are contraindicated or not tolerated, entecavir continues to represent a clinically sound and guideline-supported choice.